Karen A. Reeves
Publications by Year
Research Areas
Estrogen and related hormone effects, Growth Hormone and Insulin-like Growth Factors, HER2/EGFR in Cancer Research, Cancer, Hypoxia, and Metabolism, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection(2007)343 cited
- → The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors(2008)163 cited
- → Differential Mechanisms of Acquired Resistance to Insulin-like Growth Factor-I Receptor Antibody Therapy or to a Small-Molecule Inhibitor, BMS-754807, in a Human Rhabdomyosarcoma Model(2010)115 cited
- → Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring(2007)86 cited
- → Dual IGF-1R/InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer(2011)72 cited
- → Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro(2008)61 cited
- → Insulin Receptor (IR) Pathway Hyperactivity in IGF-IR Null Cells and Suppression of Downstream Growth Signaling Using the Dual IGF-IR/IR Inhibitor, BMS-754807(2010)41 cited
- → IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines(2014)30 cited
- → Effect of Palmitoyl Carnitine Isopropyl Ester on the Actions of BAY K 8644 and Norepinephrine in the Perfused Rat Heart(1995)4 cited
- → Identification of pharmacogenomic markers for predicting sensitivity to BMS-354825, a SRC/ABL kinase inhibitor(2005)3 cited